Two patents currently held, every record listed here
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2037. from the record
Of the 3 now held by other companies, 3 name Biohaven Therapeutics Ltd. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2037
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2043.20252030203520402043
3 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Aug 2037 · High confidence
Also notable
Ends Mar 2039 · High confidence
Antibody-Recruiting Molecules for the Treatment of Cancer
US 10,780,084
Granted 2020. Computed term ends 2037.
CD16A Binding Agents and Uses Thereof
US 12,162,892
Granted 2024. Too new for citation comparison; protection runs to 2039.
Formerly held, still cited
Notable
Ends Jan 2039 · High confidence
Granted 2023. Computed term ends 2039.
now held by Biohaven Therapeutics Ltd.
Also notable
Ends Nov 2043 · High confidence
Granted 2026. Too new for citation comparison; protection runs to 2043.
now held by Biohaven Therapeutics Ltd.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| CD16A Binding Agents and Uses Thereof | 1 in force | to Mar 2039 |
| Antibody-Recruiting Molecules for the Treatment of Cancer | 1 in force | to Aug 2037 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,780,084 | Antibody-Recruiting Molecules for the Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 12,162,892 | CD16A Binding Agents and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 3 patents in force now held by others · 3 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.